Literature DB >> 10587103

Radiosynthesis and biodistribution of 123I-labeled antagonists of the histamine H3 receptor as potential SPECT ligands.

A D Windhorst1, H Timmerman, R P Klok, F G Custers, W M Menge, R Leurs, H Stark, W Schunack, E G Gielen, M J van Kroonenburgh, J D Herscheid.   

Abstract

We have synthesized three 123I-labeled histamine H3 receptor ligands, i.e., [123I]GR 190028, [123I]FUB 271, and [123I]iodoproxyfan, in moderate to good radiochemical yields via a Cu+-assisted I-for-123I exchange method. Biodistribution in the rat of these compounds revealed high hepatic and pulmonary uptake. Brain uptake was moderate, but for [123I]iodoproxyfan, brain uptake was high enough for a pilot single photon emission computed tomography (SPECT) study in the rabbit. However, for this compound, the cerebral uptake could not be blocked by a pretreatment with [R]-alpha-methylhistamine, a selective, high-affinity histamine H3 receptor agonist, both in the SPECT study in the rabbit and in the biodistribution study in the rat. Apparently, [123I]iodoproxyfan is binding to a non-H3 receptor binding site. None of the three investigated compounds is suitable for use as a SPECT ligand for the H3 receptor in the brain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10587103     DOI: 10.1016/s0969-8051(99)00014-1

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  2 in total

1.  Use of the H3 receptor antagonist radioligand [3H]-A-349821 to reveal in vivo receptor occupancy of cognition enhancing H3 receptor antagonists.

Authors:  T R Miller; I Milicic; J Bauch; J Du; B Surber; K E Browman; K Marsh; M Cowart; J D Brioni; T A Esbenshade
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

2.  Assessment of [125I]WYE-230949 as a novel histamine H3 receptor radiopharmaceutical.

Authors:  David Y Lewis; Sue Champion; David Wyper; Deborah Dewar; Sally Pimlott
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.